BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 24326823)

  • 1. Does immunohistochemistry affect response to therapy and survival of inoperable non-small cell lung carcinoma patients? A survey of 145 stage III-IV consecutive cases.
    Pelosi G; Haspinger ER; Bimbatti M; Leone G; Paolini B; Fabbri A; Tamborini E; Perrone F; Testi A; Garassino M; Maisonneuve P; de Braud F; Pilotti S; Pastorino U
    Int J Surg Pathol; 2014 Apr; 22(2):136-48. PubMed ID: 24326823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validity of using immunohistochemistry to predict treatment outcome in patients with non-small cell lung cancer not otherwise specified.
    Ota T; Kirita K; Matsuzawa R; Udagawa H; Matsumoto S; Yoh K; Niho S; Ishii G; Goto K
    J Cancer Res Clin Oncol; 2019 Oct; 145(10):2495-2506. PubMed ID: 31494736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ΔNp63 (p40) and thyroid transcription factor-1 immunoreactivity on small biopsies or cellblocks for typing non-small cell lung cancer: a novel two-hit, sparing-material approach.
    Pelosi G; Fabbri A; Bianchi F; Maisonneuve P; Rossi G; Barbareschi M; Graziano P; Cavazza A; Rekhtman N; Pastorino U; Scanagatta P; Papotti M
    J Thorac Oncol; 2012 Feb; 7(2):281-90. PubMed ID: 22071786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of EGFR protein expression by immunohistochemistry using H-score and the magnification rule: re-analysis of the SATURN study.
    Mazières J; Brugger W; Cappuzzo F; Middel P; Frosch A; Bara I; Klingelschmitt G; Klughammer B
    Lung Cancer; 2013 Nov; 82(2):231-7. PubMed ID: 23972450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic implications of neuroendocrine differentiation and hormone production in patients with Stage I nonsmall cell lung carcinoma.
    Pelosi G; Pasini F; Sonzogni A; Maffini F; Maisonneuve P; Iannucci A; Terzi A; De Manzoni G; Bresaola E; Viale G
    Cancer; 2003 May; 97(10):2487-97. PubMed ID: 12733148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of non-small-cell lung cancer-not otherwise specified immunophenotyping on treatment outcome.
    Righi L; Vavalà T; Rapa I; Vatrano S; Giorcelli J; Rossi G; Capelletto E; Novello S; Scagliotti GV; Papotti M
    J Thorac Oncol; 2014 Oct; 9(10):1540-6. PubMed ID: 25521399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemical screening for anaplastic lymphoma kinase (ALK) rearrangement in advanced non-small cell lung cancer patients.
    Park HS; Lee JK; Kim DW; Kulig K; Kim TM; Lee SH; Jeon YK; Chung DH; Heo DS
    Lung Cancer; 2012 Aug; 77(2):288-92. PubMed ID: 22465695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunohistochemistry evaluation of biomarker expression in non-small cell lung cancer (Pharmacogenoscan study).
    Toffart AC; Timsit JF; Couraud S; Merle P; Moro-Sibilot D; Perol M; Mastroianni B; Souquet PJ; Girard N; Jeannin G; Romand P; Chatellain P; Vesin A; Brambilla C; Brambilla E
    Lung Cancer; 2014 Feb; 83(2):182-8. PubMed ID: 24388706
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blood vessel invasion is a major feature and a factor of poor prognosis in sarcomatoid carcinoma of the lung.
    Vieira T; Antoine M; Ruppert AM; Fallet V; Duruisseaux M; Giroux Leprieur E; Poulot V; Rabbe N; Sclick L; Beau-Faller M; Lacave R; Lavole A; Cadranel J; Wislez M
    Lung Cancer; 2014 Aug; 85(2):276-81. PubMed ID: 24997135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High coexpression of both EGFR and IGF1R correlates with poor patient prognosis in resected non-small-cell lung cancer.
    Gately K; Forde L; Cuffe S; Cummins R; Kay EW; Feuerhake F; O'Byrne KJ
    Clin Lung Cancer; 2014 Jan; 15(1):58-66. PubMed ID: 24210543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyto-histologic agreement in pathologic subtyping of non small cell lung carcinoma: review of 602 fine needle aspirates with follow-up surgical specimens over a nine year period and analysis of factors underlying failure to subtype.
    da Cunha Santos G; Lai SW; Saieg MA; Geddie WR; Pintilie M; Tsao MS; Boerner SL; Hwang D
    Lung Cancer; 2012 Sep; 77(3):501-6. PubMed ID: 22656670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p40 & thyroid transcription factor-1 immunohistochemistry: A useful panel to characterize non-small cell lung carcinoma-not otherwise specified (NSCLC-NOS) category.
    Walia R; Jain D; Madan K; Sharma MC; Mathur SR; Mohan A; Iyer VK; Kumar L
    Indian J Med Res; 2017 Jul; 146(1):42-48. PubMed ID: 29168459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ΔNp63 (p40) distribution inside lung cancer: a driver biomarker approach to tumor characterization.
    Pelosi G; Rossi G; Cavazza A; Righi L; Maisonneuve P; Barbareschi M; Graziano P; Pastorino U; Garassino M; de Braud F; Papotti M
    Int J Surg Pathol; 2013 Jun; 21(3):229-39. PubMed ID: 23486764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An association between preoperative anemia and decreased survival in early-stage non-small-cell lung cancer patients treated with surgery alone.
    Yovino S; Kwok Y; Krasna M; Bangalore M; Suntharalingam M
    Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1438-43. PubMed ID: 16029805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor expression of S100A6 correlates with survival of patients with stage I non-small-cell lung cancer.
    De Petris L; Orre LM; Kanter L; Pernemalm M; Koyi H; Lewensohn R; Lehtiö J
    Lung Cancer; 2009 Mar; 63(3):410-7. PubMed ID: 18620780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive value of MMP-7 expression for response to chemotherapy and survival in patients with non-small cell lung cancer.
    Liu H; Zhang T; Li X; Huang J; Wu B; Huang X; Zhou Y; Zhu J; Hou J
    Cancer Sci; 2008 Nov; 99(11):2185-92. PubMed ID: 18823373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EGFR and TTF-1 gene amplification in surgically resected lung adenocarcinomas: clinicopathologic significance and effect on response to EGFR-tyrosine kinase inhibitors in recurred cases.
    Lee JS; Kim HR; Lee CY; Shin M; Shim HS
    Ann Surg Oncol; 2013 Sep; 20(9):3015-22. PubMed ID: 23525704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bax, bcl-2 and c-kit expression in non-small-cell lung cancer and their effects on prognosis.
    Yaren A; Oztop I; Kargi A; Ulukus C; Onen A; Sanli A; Binicier O; Yilmaz U; Alakavuklar M
    Int J Clin Pract; 2006 Jun; 60(6):675-82. PubMed ID: 16805752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical significance of IGF1R expression in non-small-cell lung cancer.
    Nakagawa M; Uramoto H; Oka S; Chikaishi Y; Iwanami T; Shimokawa H; So T; Hanagiri T; Tanaka F
    Clin Lung Cancer; 2012 Mar; 13(2):136-42. PubMed ID: 22133293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of histology and biomarkers on first-line treatment of advanced non-small cell lung cancer in routine care setting: baseline results of an observational study (FRAME).
    Schnabel PA; Smit E; Carpeño Jde C; Leśniewski-Kmak K; Aerts J; Kraaij K; Visseren-Grul C; Dyachkova Y; Taipale K; Girvan A; Moro-Sibilot D
    Lung Cancer; 2012 Dec; 78(3):263-9. PubMed ID: 23040326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.